Product

Company

Clareo Health | Neuromodulation in COVID-19 Patients

NCT04808284·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

D'Or Institute for Research and Education

With

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

suspected or confirmed diagnosis for SARS-CoV-2;
ability to understand and execute the proposed protocol;
vital signs (body temperature \<38ºC, blood pressure between 90 x 60mmHg and 140 x 90 mmHg, respiratory rate between 12 e 30 bpm).

dyspnea or signs of respiratory effort;
SpO2 ≤ 90%;
hemodynamic instability;
deep vein thrombosis, active bleeding, use of cardiac pacemaker;
injury, pain or metallic implants in the cranium or scalp;
seizure history;
suspected or confirmed pregnancy;
concomitant or previous rheumatic or neurological diseases;
severe psychiatric diseases (schizophrenia, bipolar disorder, intellectual disability);
severe musculoskeletal and/or integumentary disorders;
severe psychiatric disorders;
severe liver or kidney disease.

The record

StatusCompleted

PhasePhase 1–2

Taking part60

StartedAug 2021

UpdatedOct 14, 2021

Conditions

Where1

D'Or Institute for Research and Education (IDOR)
Rio de Janeiro, Rio de Janeiro, Brazil